5-HT1A gene promoter polymorphism and [18F]MPPF binding potential in healthy subjects: a PET study by Lothe, Amélie et al.
Lothe et al. Behavioral and Brain Functions 2010, 6:37
http://www.behavioralandbrainfunctions.com/content/6/1/37
Open Access RESEARCH
© 2010 Lothe et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Research 5-HT1A gene promoter polymorphism and 
[18F]MPPF binding potential in healthy subjects: a 
PET study
Amélie Lothe*1,2, Claudette Boni3, Nicolas Costes4, Sandrine Bouvard1, Philip Gorwood3, Franck Lavenne4, 
Marion Alvarez4 and Philippe Ryvlin1,2,5
Abstract
Background: Previous Positron Emission Tomography (PET) studies of 5-HT1A receptors have shown an influence of 
several genetic factors, including the triallelic serotonin transporter gene-linked polymorphic region on the binding 
potential (BPND) of these receptors. The aim of our study was to investigate the relationship between a 5-HT1A promoter 
polymorphism and the binding potential of another selective 5-HT1A receptor antagonist, [18F]MPPF, in healthy 
subjects.
Methods: Thirty-five volunteers, including 23 women, underwent an [18F]MPPF scan and were genotyped for both the 
C(-1019)G 5-HT1A promoter polymorphism and the triallelic serotonin transporter gene-linked polymorphic region. We 
used a simplified reference tissue model to generate parametric images of BPND. Whole brain Statistical Parametric 
Mapping and raphe nuclei region of interest analyses were performed to look for an association of [18F]MPPF BPND with 
the C(-1019)G 5-HT1A promoter polymorphism.
Results: Among the 35 subjects, 5-HT1A promoter genotypes occurred with the following frequencies: three G/G, 
twenty-one G/C, and eleven C/C. No difference of [18F]MPPF BPND between groups was observed, except for two 
women who were homozygote carriers for the G allele and showed greater binding potential compared to other age-
matched women over the frontal and temporal neocortex. However, the biological relevance of this result remains 
uncertain due to the very small number of subjects with a G/G genotype. These findings were not modified by 
excluding individuals carrying the S/S genotype of the serotonin transporter gene-linked polymorphic region.
Conclusions: We failed to observe an association between the C(-1019)G 5-HT1A promoter polymorphism and 
[18F]MPPF binding in healthy subjects. However our data suggest that the small number of women homozygote for 
the G allele might have greater [18F]MPPF BPND relative to other individuals. This finding should be confirmed in a larger 
sample.
Background
The binding potential (BP) of [11C]WAY100635 at 5-
HT1A receptors is reported to be influenced by several
genetic factors, including the serotonin transporter gene-
linked polymorphic region (5-HTTLPR) [1,2]. We have
recently evaluated the impact of this polymorphism on
the BP of another selective 5-HT1A receptor antagonist,
[18F]MPPF (4-(2'-methoxyphenyl)-1-[2'-(N-2-pirydynyl)-
p-fluorobenzamido]-ethyl-piperazine), given that
[11C]WAY100635 and [18F]MPPF demonstrate several
functional differences [3]. [18F]MPPF is characterized by
an affinity for 5-HT1A receptors in rat hippocampal mem-
brane homogenates (Ki = 3.3 nM) which is lower than
that for [11C]WAY100635 (Ki = 0.8 nM) [4], and more
comparable to that of endogenous serotonin (5-HT) (Ki
= 4.17 nM) [5]. Furthermore, in contrast to
[11C]WAY100635, [18F]MPPF is reported to be sensitive
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in vivo to the concentration of extracellular 5-HT [6-8].
Accordingly, we previously observed that healthy women
homozygote carriers of the S allele of 5-HTTLPR had sig-
nificantly greater [18F]MPPF BP than carriers of at least
one LA allele [3].
In the present study, we have extended our research to
examine a possible association between C(-1019)G 5-
HT1A promoter polymorphism and [18F]MPPF BP. This
polymorphism is located in the regulatory region of the
5-HT1A promoter which inhibits transcriptional repres-
sion of the 5-HT1A gene [9,10], and is part of a 26 base
pair imperfect palindrome [11]. This palindromic region
is recognized by two transcription factors; the nuclear
deformed epidermal autoregulatory factor (NUDR, Deaf-
1) and Hes5. This recognition occurs in an allele-specific
manner, such that these proteins bind to the C allele but
not the G allele. The G allele is reported to abolish repres-
sion by NUDR in raphe but not hippocampal neuron cul-
tures [11]. Thus, the G allele is supposedly associated
with higher expression of 5-HT1A receptors in the raphe
nuclei and decreased 5-HT release, consistent with the
association reported between G/G genotype and major
depression [11,12].
The association of C(-1019)G 5-HT1A promoter poly-
morphism and 5-HT1A receptor binding has been studied
i n  h u m a n s  i n  t h r e e  [ 11C]WAY-100 635 PET studies
[1,12,13]. One of these studies was performed using a
homogenous group of healthy subjects and failed to
detect any significant relationship between C(-1019)G 5-
HT1A promoter polymorphism and [11C]WAY-100635 BP
[1]. The other two studies, performed using a mixed pop-
ulation of depressed and healthy individuals, demon-
strated greater BP in the raphe nuclei, the amygdala, and
the hippocampus in carriers with at least one G allele
compared to the C/C genotype [12,13].
In the present study, we sought to identify possible
associations between C(-1019)G 5-HT1A promoter poly-
morphism and [18F]MPPF BP in a homogenous group of
healthy subjects, and further examined the potential con-
founding impact of triallelic 5-HTTLPR polymorphism.
Methods
Thirty-five healthy subjects were selected on the basis of
(i) no sign or history of neurological, psychiatric, cardio-
vascular, pleuro-pulmonary or haematological illness, (ii)
no ongoing central nervous system (CNS)-active treat-
ment including neuroleptic, antiparkinsonian, methyl-
dopa, β-blocker, monoamine oxidase inhibitor-A or -B,
tricyclic antidepressant, thymoregulator or antimigraine
treatment, (iii) no hormone replacement therapy, and (iv)
a score below the threshold for depression (< 7) for the
GHQ-28. All subjects gave their informed consent to par-
ticipate in this study, which was approved by the local
Ethics committee (CCPPRB, Centre Léon Bérard, Lyon)
in accordance with the Declaration of Helsinki and
French regulations on Biomedical Research.
Genomic DNA was extracted from endobuccal cell
swabs, according to the BuccalAmp DNA Extraction Kit
from Epicentre. Allele-specific polymerase chain reaction
(PCR) amplification was performed according to the pro-
tocol originally described by Hong et al. [14], and enabled
us to classify each subject into one of the three following
groups: C/C, C/G or G/G. In addition, all subjects were
genotyped for the triallelic 5-HTTLPR polymorphism
and classified as S/S, S/LA and LA/LA (as reported previ-
ously; see [3] for details).
All subjects also underwent a 3-D anatomical T1-
weighted sequence on a 1.5-T Siemens Magnetom scan-
ner (Siemens AG, Erlangen, Germany). Data were
acquired in the sagittal plane with 1 mm3 voxels and an
anatomical volume that covered the whole brain. Mag-
netic resonance images (MRIs) were visually analysed by
a neurologist to ensure that no brain lesion or malforma-
tion was present.
The methodology of tracer production, scan acquisi-
tion and data pre-processing was the same as previously
described [15]. To summarize, [18F]MPPF was acquired
with a CTI Exact HR+ scanner for 60 min after the injec-
tion of 186 ± 24 MBq of [18F]MPPF. Specific activity
ranged between 37 and 111 GBq/μmol [16]. Sinograms
were normalized, attenuated, scatter corrected and then
reconstructed with filtered backprojection (Hanning fil-
ter: cutoff, 0.5 cycle/voxel). This yielded a dynamic set of
35 volumes of 128 × 128 × 63 voxels with a voxel size of
2.04 × 2.04 × 2.42 mm3. All PET acquisitions were per-
formed during the afternoon, and the patient's level of
vigilance was supervised throughout the entire PET
acquisition to avoid somnolence or sleep.
Parametric images of binding potential (BPND [non dis-
placeable], according to consensus nomenclature [17])
values were obtained using a simplified reference tissue
model (SRTM) [18] previously validated by our group for
[18F]MPPF studies [19]. Cerebellar white matter, which is
assumed to be devoid of 5-HT1A specific binding [20],
was used as a reference region [19]. Parametric images of
BPND were transformed into a standard stereotaxic space
(MNI template of the ICBM Project, [21]) using Statisti-
cal Parametric Mapping (SPM2, Wellcome Trust Centre
for Neuroimaging, UCL, London, UK; http://www.
fil.ion.ucl.ac.uk/spm/). Normalized BPND  images were
then smoothed using an 8 × 8 × 8 mm FWHM isotropic
Gaussian kernel [22].
The BPND global values were extracted for all subjects
using SPM and were compared among C/C, C/G and G/
G subgroups using an ANOVA and the Statistical Pro-Lothe et al. Behavioral and Brain Functions 2010, 6:37
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gram for the Social Sciences (SPSS, version 12). The sig-
nificance threshold was set at p < 0.05.
We searched for possible statistical differences between
BPND images according to C(-1019)G 5-HT1A promoter
functional polymorphism using the linear model at each
and every voxel [23]. Given that all subjects are healthy
volunteers, we hypothesize an invariant residual variance
between groups. All analyses were performed using
SPM2 on the normalized smoothed parametric BPND
images. We chose an "ANCOVA by condition" design
matrix, an explicit mask that includes the whole brain
and brainstem, and uses global BP as a co-variable of no
interest.
To further address the potential confounding role of
gender, we performed subanalyses of the 23 women and
12 men, separately. Age was considered as a co-variable
of no interest. We retained clusters with a threshold of p
< 0.001 uncorrected at the voxel level, and a corrected
threshold of p < 0.05 at the cluster level after SPM stan-
dard correction for multiple comparisons.
We further analysed [18F]MPPF BPND in the dorsal and
median raphe nuclei using a region of interest (ROI)
delineated on the average [18F]MPPF BPND  image
obtained from the normalized scans of our subjects by
setting the threshold activity at 90% of the local maxi-
mum in the brainstem. The ROI was then displayed on
the MRI template to verify its proper location in the peri-
aqueducal grey matter of the brainstem. This ROI
extended on the 13 consecutive slices displaying the
raphe, with a total volume of 1400 mm3. For each subject,
ROIs were then applied on normalized and smoothed
parametric BPND images to extract a mean BPND value for
this ROI. The mean BPND values of raphe were compared
among C/C, C/G and G/G subgroups in the total popula-
tion, as well as in women and men separately, using an
ANOVA and SPSS (version 12). The global BPND values
and age were considered as co-variables of no-interest.
The significance threshold was set at p < 0.05.
In order to rule out that our findings were influenced
by the previously demonstrated association between 5-
HTTLPR polymorphism and [18F]MPPF BPND  [3], we
reprocessed all above analyses after excluding the eight
subjects who were homozygote carriers of the S allele
(four men and four women).
Results
All of our 35 healthy subjects (12 men and 23 women)
were Caucasian. The allele frequencies of C(-1019)G 5-
HT1A  promoter polymorphisms were comparable to
those of others studies with European subjects; 38.6%
with the G allele, 61.4% with the C allele, and three indi-
viduals (8.57%) homozygous for the G allele [11,13].
Accordingly, the genotype distribution (see table 1) was
in Hardy-Weinberg equilibrium (χ2 = 2.48; df = 1, p =
0.11). Regarding 5-HTTLPR polymorphism, homozygote
carriers of the S allele were distributed as follows: two
among the C/C group, six among the C/G group and
none among the G/G group.
There was no difference in the mean global BPND
between the various allelic subgroups (C/C group: mean
± SD = 0.52 ± 0.09; C/G group: mean ± SD = 0.58 ± 0.17;
G/G group: mean ± SD = 0.48 ± 0.13; p = 0.7), nor any
significant influence of gender (p = 0.1).
SPM analyses
When considering the whole sample of 35 subjects or the
subgroup of 12 men, no significant difference in
[18F]MPPF BPND was observed between the three geno-
types of C(-1019)G 5-HT1A promoter polymorphism (C/
C, C/G, G/G).
In contrast, when the analysis was restricted to the sub-
group of 23 women, we found significantly greater
regional [18F]MPPF BPND in homozygous carriers for the
G allele compared to C/C and C/G individuals, while no
difference was observed between these two latter popula-
tions. Differences between G/G and C/C subjects were
observed in the anterior portion of the left superior and
middle frontal gyri (pcorrected = 0.042) as well as over the
right and left orbitofrontal cortex (pcorrected = 0.001) (see
table 2), whereas differences between G/G and C/G indi-
viduals were found in the right and left mesial frontal pole
(pcorrected < 0.001), the anterior aspect of the right middle
and inferior temporal gyri (pcorrected = 0.004), the right
orbitofrontal cortex (pcorrected = 0.014) and the right fron-
tal dorsolateral cortex (pcorrected = 0.007) (see additional
files 1 and 2). The same significant clusters were observed
when women with C/G and C/C genotypes were com-
bined and compared with the G/G group (see figure 1 and
table 2).
Reprocessing the above analyses after exclusion of the
eight homozygote carriers for the S allele of the 5-
HTTLPR polymorphism only slightly modified our find-
ings. Indeed, only the subgroup of 19 women demon-
strated significant differences in [18F]MPPF BPND in
relation to C(-1019)G 5-HT1A promoter polymorphism,
with greater BPND for those with G/G compared to those
with C/C and C/G (see table 3). Significant clusters
affected the same brain regions as those described above,
but were more extensive and included the bulbar sero-
toninergic nuclei (pcorrected = 0.021) (see figure 2).
ROI analysis of the dorsal and median raphe nuclei
We failed to identify an association between C(-1019)G
5-HT1A promoter polymorphism and [18F]MPPF BPND in
the dorsal and median raphe, even when the analysis was
restricted to women, and also after excluding homozy-Lothe et al. Behavioral and Brain Functions 2010, 6:37
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gous carriers for the S allele for 5-HTTLPR polymor-
phism (see table 4).
Discussion
In this PET study, no clear cut association was identified
between C(-1019)G 5-HT1A promoter functional poly-
morphism and [18F]MPPF/5-HT1A receptor binding. This
negative finding could reflect an unsatisfactory statistical
power . However it should be stressed that the primary
analysis upon which this conclusion is drawn contrasted
21 subjects with C/G genotype and 11 subjects with C/C
genotype, in accordance with the general empiric consen-
sus that neuroimaging studies that include groups of 12
subjects benefit from adequate statistical power. The 9
additional subjects with C/G genotype are likely to com-
pensate the marginally reduced statistical power related
to the 11 subjects in the C/C group. Overall, we believe
that the statistical power of our main negative findings,
though necessarily uncertain, is fully consistent with that
used in the great majority of PET studies worldwide.
Table 1: C(-1019)G 5-HT1A promoter polymorphism distribution.
C(-1019)G 5-HT1A promoter polymorphism C/C C/G G/G Total
Number of subjects (% of population) 11 (31.4%) 21 (60%) 3 (8.6%) 35 (100%)
% of women 54.5% 71.43% 66.7% 65.7%
Mean age ± SD 43.9 ± 14.4 44.1 ± 12.6 43.3 ± 10 44 ± 12.7
Number of subjects with S/S genotype (%) 2 (18.2%) 6 (28.6%) 0 8 (22.9%)
Table 2: SPM analyses performed in the subgroup of 23 women. k is the cluster size expressed in voxels. 
23 women
contrast anatomic brain regions covered MNI coordinates (x, y, z (mm)) Z score, k, p
GG-CC left anterior superior and middle frontal gyri (F1 and F2) -16; 16; 52 Z = 4.48, k = 239, p = 0.042*
right and left orbitofrontal cortex 22; 58; -12 Z = 4.31, k = 550, p = 0.001*
GG-CG right and left mesial frontal pole 4; 62; 8 Z = 5.04, k = 1884, p < 0.001*
right anterior second and third temporal cortex (T2, T3) 60; -22; -18 Z = 4.61, k = 416, p = 0.004*
right orbitofrontal cortex 28; 40; -18 Z = 4.48, k = 313, p = 0.014*





GG-(CG+CC) right and left mesial frontal pole 4; 62; 8 Z = 4.79, k = 1407, p < 0.001*
right anterior second and third temporal cortex (T2, T3) 60; -22; -18 Z = 4.52, k = 283, p = 0.022*
left anterior superior and middle frontal gyri (F1 and F2) -16; 16; 52 Z = 4.35, k = 253, p = 0.034*
right orbitofrontal cortex 28; 40; -18 Z = 4.29, k = 298, p = 0.018*
right dorsolateral frontal cortex 44; 38; 26 Z = 3.92, k = 324, p = 0.012*
left anterior inferior frontal gyrus (F3) -46; 40; 4 Z = 3.74, k = 312, p = 0.015*
(CG+CC)-GG NS
NS: no significant. Only significant findings are shown.Lothe et al. Behavioral and Brain Functions 2010, 6:37
http://www.behavioralandbrainfunctions.com/content/6/1/37
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Figure 1 SPM analysis of 23 women demonstrating differences between G/G genotype and C/G and C/C genotypes. Women with G/G gen-
otype demonstrated greater [18F]MPPF BPND than women with C/G and C/C genotypes in the right and left mesial frontal pole, the right second and 
third temporal cortex (T2, T3), the left superior and middle frontal gyri (F1 and F2), the right orbitofrontal cortex, the right dorsolateral frontal cortex 
and the left inferior frontal gyrus (F3). All displayed regions had a height threshold at pcorrected < 0.05 at the cluster level after correction for multiple 
comparisons. Colour scale: Z score.Lothe et al. Behavioral and Brain Functions 2010, 6:37
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Table 3: SPM analyses performed in the subgroup of 19 women after the exclusion of the homozygote carriers of the S 
allele of the 5-HTTLPR polymorphism.
19 women
contrast Anatomic brain regions covered MNI coordinates (x, y, z (mm)) Z score, k, p
GG-CC bulbar serotoninergic nuclei 0; -22; -46 Z = 4.75, k = 244, p = 0.021*
left superior and middle frontal gyri (F1 and F2) -16; 18; 50 Z = 4.73, k = 480, p = 0.001*
right mesial frontal and left supplementary motor area 2; -14; 58 Z = 4.55, k = 885, p < 0.001*
left and right mesial frontal pole -2; 60; -2 Z = 4.52, k = 646, p < 0.001*
left lateral middle temporal cortex (T2) -58; -14; -26 Z = 4.20, k = 198, p = 0.048*
right anterior mesial frontal 12; 36; 38 Z = 4.12, k = 247, p = 0.020*
left anterior inferior frontal gyrus (F3) -46; 42; 6 Z = 3.66, k = 298, p = 0.009*
GG-CG right and left mesial frontal pole 4; 62; 10 Z = 5.14, k = 3248, p < 0.001*
right lateral orbitofrontal cortex 26; -38; -20 Z = 4.95, k = 357, p = 0.003*
right parahippocampal gyrus 38; -16; -26 Z = 4.87, k = 273, p = 0.013*
right temporal pole 30; 14; -38 Z = 4.75, k = 574, p < 0.001*
right lateral second and third temporal cortex (T2, T3) 60; -22; -16 Z = 4.53, k = 545, p < 0.001*
left lateral second and third temporal cortex (T2, T3) -60; -12; -24 Z = 4.45, k = 383, p = 0.002*
left temporal pole -34; 10; -40 Z = 4.16, k = 393, p = 0.002*
right anterior superior and middle frontal gyri (F1, F2) -14; 26; 52 Z = 4.05, k = 214, p = 0.036*
right frontal operculum 52; 14; 6 Z = 3.97, k = 294, p = 0.009*
left anterior inferior frontal gyrus (F3) -42; 28; -2 Z = 3.96, k = 501, p < 0.001*





GG - (GC+CC) left and right mesial frontal pole -2; 60; -2 Z = 4.92, k = 2877, p < 0.001*
right lateral orbitofrontal cortex 26; -38; -20
right temporal pole 30; 14; -38 Z = 4.56, k = 215, p = 0.035*
left superior and middle frontal gyri (F1, F2) -16; 20; 50 Z = 4.49, k = 411, p = 0.002*
right lateral second and third temporal cortex (T2, T3) 60; -22; -16 Z = 4.43, k = 342, p = 0.004*
left lateral middle temporal cortex (T2) -58; -12; -24 Z = 4.37, k = 321, p = 0.006*
left superior frontal gyrus (F1) -42; 0; 42 Z = 4.22, k = 212, p = 0.037*
right frontal operculum 54; 12; 6 Z = 3.88, k = 234, p = 0.025*
left anterior inferior frontal gyrus (F3) -42; 28; -2 Z = 3.87, k = 469, p = 0.001*
right dorsolateral frontal cortex 44; 38; 26 Z = 3.82, k = 368, p = 0.003*
(GC+CC) - GG NS
k is the cluster size expressed in voxels. Only significant findings are shown. NS: no significant.Lothe et al. Behavioral and Brain Functions 2010, 6:37
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The women homozygote carriers for the G allele
appeared to demonstrate greater [18F]MPPF BPND in vari-
ous frontal and temporal brain regions than those carry-
ing at least one C allele. However, the significance of this
latter finding, which was shown to be independent of the
previously reported association between 5-HTTLPR
polymorphism and [18F]MPPF BPND in women, remains
uncertain, due to the small number of individuals with a
G/G genotype. Indeed, only three of our 35 healthy sub-
jects (9%), including two women, were homozygous for
the G allele, a figure consistent with the 8-10% prevalence
of this genotype in the general population. This small
number of subjects carries the risk of spurious PET find-
ings, despite the strong statistical significance of our SPM
analysis. It must be stressed that there is no easy solution
to this limitation. The number of controls who can be
scanned in any given PET centre is constrained by ethical
issues, providing little justification to study larger popula-
tions than those reported here. Conversely, mixing data
from healthy controls with those from patients suffering
from various psychiatric disorders, reported in previous
studies [12,13], makes it impossible to identify the direct
effect of genetic polymorphism from that of its associated
pathologies. An alternative for a future study would be to
first screen the C(-1019)G 5-HT1A promoter polymor-
phism in a sufficiently large series of normal subjects in
o r d e r  t o  s e l e c t  a n  a p p r o p r i a t e  n u m b e r  o f  s u b j e c t s
homozygote for the G allele who will then undertake a
[18F]MPPF PET study.
There is still very few data regarding the functional
impact of C(-1019)G 5-HT1A promoter polymorphism on
the serotoninergic system. Direct assessment of this poly-
morphism in rodents is made difficult by the fact that it is
not present in rat or mouse genes. However, the G(-1019)
allele was shown to abolish the repression of 5-HT1A
autoreceptor transcription mediated in the raphe nuclei
by NUDR in vitro [11]. The resulting over-expression of
5-HT1A autoreceptors should lead to a reduction of 5-HT
release and a possible homeostatic over-expression of
post-synaptic 5-HT1A receptors [12]. However, not all
studies support this view. In particular, the mRNA
expression and protein density of 5-HT1A post-synaptic
receptors were shown not to respond to a reduced 5-HT
concentration following lesion of the raphe or adminis-
tration of PCPA [24,25]. Moreover NUDR can act as a
repressor or an enhancer, depending on cell type and pro-
moter sequence [26,27]. In particular, it was found that
NUDR enhances rather than represses 5-HT1A transcrip-
tional activity in hippocampal and septal cells [11]. Over-
all, the complex organisation of gene regulation in vivo, as
well as the possibility of compensatory mechanisms,
makes it difficult to draw any firm conclusion regarding
the impact of C(-1019)G 5-HT1A  promoter polymor-
phism on 5-HT1A receptor expression in humans.
Three [11C]WAY-100635 PET studies have previously
investigated this issue, and have reported discordant
results [1,12,13]. Two series included a mixed population
Figure 2 SPM analysis performed after exclusion of homozygote carriers for the S allele of the 5-HTTLPR polymorphism. Of the subgroup of 
19 women analysed, a comparison of the G/G and C/C genotypes demonstrated comparable findings to those illustrated in figure one, with an addi-
tional significant cluster over the bulbar serotoninergic nuclei. Colour scale: Z score.
Table 4: Mean [18F]MPPF BPND values of raphe nuclei.
C (-1019)G 5-HT1A promoter polymorphism C/C C/G G/G
women 0.25 ± 0.07 0.29 ± 0.13 0.33 ± 0.22
mean BPND ± SD men 0.17 ± 0.03 0.22 ± 0.04 0.14
all 0.21 ± 0.07 0.27 ± 0.11 0.27 ± 0.19Lothe et al. Behavioral and Brain Functions 2010, 6:37
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of depressed or bipolar patients and healthy subjects, and
both found greater [11C]WAY-100635 BP in carriers of at
least one G allele compared to the C/C genotype, over the
raphe nuclei, the amygdala, and the hippocampus [12,13].
Conversely, the third series, which, like our study, investi-
gated a homogeneous population of normal individuals,
failed to detect any association between C(-1019)G 5-
HT1A polymorphism and [11C]WAY-100635 BP [1]. The
data from these three series also differ in terms of gender
distribution, with a greater [11C]WAY-100635 BP
reported in women in the two mixed population studies
[12,13]. In our studies, gender proved to be a crucial fac-
tor regarding the genetic variables that influence
[18F]MPPF BPND which association with 5-HTTLPR and
C(-1019)G 5-HT1A  polymorphisms were found exclu-
sively in women [3]. Similarly, another PET study demon-
strated an association between monoamine oxidase A
(MAO-A) polymorphism and [11C]WAY-100635 BP
selectively in women [28]. Other preclinical and clinical
reports support sexual dimorphism in serotoninergic
neurotransmission (see for review [29]). In particular,
women and men differ in terms of blood and cerebral 5-
HT concentration [30,31], and availability of 5-HT1A
receptors [15].
Other important methodological issues need to be con-
sidered when interpreting available PET data, including
age of subjects, data analysis, and the molecular charac-
teristics of ligands. Binding of [11C]WAY-100 635 and
[18F]MPPF to 5-HT1A receptor is reported to significantly
decline with age, especially in women [32,33,15,34]. We
have addressed this issue by incorporating age as a co-
variable of no-interest in our analyses, in contrast to most
previous studies which have failed to address this or pro-
vide information regarding the age distribution in each
genotype subgroups. It should also be noted that we
searched for differences between groups at each and
every voxel using SPM analysis, in contrast to previous
studies which have solely used different sets of predefined
ROIs. However, the main difference between our study
and previous series lies in the molecular characteristics of
[18F]MPPF compared to [11C]WAY-100 635. Specifically,
[18F]MPPF exhibits a relatively low affinity for 5-HT1A
receptors, comparable to that of endogenous 5-HT , and
appears to selectively bind to externalized receptors [8],
whereas [11C]WAY-100 635 demonstrates greater affinity
and a non-selective binding to both internalized and
externalized receptors [35]. These differences may make
[18F]MPPF more sensitive than [11C]WAY-100 635 to the
extracellular concentration of 5-HT, as suggested in
rodents [6]. In particular, [18F]MPPF BPND might increase
as a result of decreased 5-HT release [36]. Accordingly,
the greater [18F]MPPF BPND observed in healthy women
homozygote carriers for the G allele, if confirmed, could
reflect the downstream consequences of an increased
expression of 5-HT1A autoreceptors in the raphe nuclei,
i.e. a decreased release of 5-HT as well as a subsequent
increased expression of post-synaptic 5-HT1A receptors.
However, the lack of clear-cut changes in [18F]MPPF
BPND over the dorsal and median raphe nuclei does not
support such a mechanism.
An original aspect of our study was to take into account
both 5-HTTLPR and C(-1019)G 5-HT1A promoter poly-
morphisms, and to ensure that any effect of the latter on
[18F]MPPF BPND was not due to an imbalanced distribu-
tion of 5-HTTLPR alleles among the different groups
considered. Interestingly, while both polymorphisms are
associated with common features regarding [18F]MPPF
BPND  (same gender specificity and greater [18F]MPPF
BPND in subjects with supposedly lower extracellular con-
centration of 5-HT), these were observed in distinct brain
regions. Whereas differences in [18F]MPPF BPND associ-
ated with 5-HTTLPR polymorphism were previously
reported predominately over paralimbic regions (para-
hippocampal, orbitofrontal, insula, cingulate) [3],
[18F]MPPF BPND associated with C(-1019)G 5-HT1A pro-
moter polymorphism, was primarily localised to the fron-
tal and temporal neocortex in this study. These
distinctive patterns might reflect the involvement of spe-
cific serotoninergic projection pathways.
Overall, our study failed to demonstrate any significant
association between C(-1019)G 5-HT1A promoter poly-
morphism and regional distribution of [18F]MPPF BPND
in our entire sample. This negative finding was also
observed in C/C and C/G women but our data suggest
that the small number of women homozygote carriers for
the G allele display greater [18F]MPPF BPND relative to
other individuals. Confirmation of this latter finding,
together with the previous studies of 5-HTTLPR poly-
morphism, indicates that these two polymorphic regions
are relevant co-variables of age and gender, which should
b e  c o n s i d e r e d  f o r  f u t u r e  [ 18F]MPPF studies in normal
individuals as well as patients.
Additional material
Additional file 1 Plot of the [18F]MPPF BPND values of 23 women at the 
peak voxel of the significant cluster in the left superior and middle 
frontal gyri (a) and in the right and left orbitofrontal cortex (b). the first 
six scans correspond to the women with C/C genotype, the scan number 7 
to 21 represent the 15 women with C/G genotype and the two last scans 
represent the two women with G/G genotype.
Additional file 2 Plot of the [18F]MPPF BPND values of 23 women at the 
peak voxel of the significant cluster in the right and left mesial frontal 
pole (a) and in the right second and third temporal cortex (b). The first 
six scans correspond to the women with C/C genotype, the scan number 7 
to 21 represent the 15 women with C/G genotype and the two last scans 
represent the two women with G/G genotype.Lothe et al. Behavioral and Brain Functions 2010, 6:37
http://www.behavioralandbrainfunctions.com/content/6/1/37
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